LLY logo

Eli Lilly and Company (LLY) Cash and cash equivalents

annual cash & cash equivalents:

$3.42B+$495.50M(+16.92%)
December 31, 2024

Summary

  • As of today (September 10, 2025), LLY annual cash & cash equivalents is $3.42 billion, with the most recent change of +$495.50 million (+16.92%) on December 31, 2024.
  • During the last 3 years, LLY annual cash & cash equivalents has fallen by -$485.40 million (-12.42%).
  • LLY annual cash & cash equivalents is now -57.39% below its all-time high of $8.03 billion, reached on December 31, 2017.

Performance

LLY Cash and cash equivalents Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Range

Earnings dates

OtherLLYbalance sheet metrics

quarterly cash & cash equivalents:

$3.55B+$325.30M(+10.10%)
June 30, 2025

Summary

  • As of today (September 10, 2025), LLY quarterly cash & cash equivalents is $3.55 billion, with the most recent change of +$325.30 million (+10.10%) on June 30, 2025.
  • Over the past year, LLY quarterly cash & cash equivalents has increased by +$182.00 million (+5.41%).
  • LLY quarterly cash & cash equivalents is now -60.76% below its all-time high of $9.04 billion, reached on September 30, 2018.

Performance

LLY quarterly cash & cash equivalents Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Range

Earnings dates

OtherLLYbalance sheet metrics

Cash and cash equivalents Formula

Cash & Cash Equivalents = Cash + Short-Term Investments

LLY Cash and cash equivalents Trends

PeriodPeriodAnnualAnnualQuarterlyQuarterly
1 y1 year+16.9%+5.4%
3 y3 years-12.4%+29.6%
5 y5 years+40.4%+48.5%

LLY Cash and cash equivalents Highs & Lows

PeriodPeriodAnnual vs highAnnual vs highAnnual vs lowAnnual vs lowQuarter. vs highQuarter. vs highQuarter. vs lowQuarter. vs low
3 y3-year-12.4%+54.8%-3.4%+60.3%
5 y5-year-12.4%+54.8%-9.3%+60.3%
alltimeall time-57.4%+743.0%-60.8%+1439.1%

LLY Cash and cash equivalents History

DateAnnualQuarterly
Jun 2025
-
$3.55B(+10.1%)
Mar 2025
-
$3.22B(-5.9%)
Dec 2024
$3.42B(+16.9%)
$3.42B(-2.7%)
Sep 2024
-
$3.52B(+4.6%)
Jun 2024
-
$3.36B(+30.1%)
Mar 2024
-
$2.59B(-11.7%)
Dec 2023
$2.93B(+32.4%)
$2.93B(+17.4%)
Sep 2023
-
$2.49B(-11.8%)
Jun 2023
-
$2.83B(-22.9%)
Mar 2023
-
$3.67B(+65.9%)
Dec 2022
$2.21B(-43.4%)
$2.21B(-19.3%)
Sep 2022
-
$2.74B(+0.2%)
Jun 2022
-
$2.74B(+6.6%)
Mar 2022
-
$2.57B(-34.3%)
Dec 2021
$3.91B(+6.2%)
$3.91B(+2.2%)
Sep 2021
-
$3.83B(+16.9%)
Jun 2021
-
$3.27B(+7.2%)
Mar 2021
-
$3.05B(-17.1%)
Dec 2020
$3.68B(+51.0%)
$3.68B(+1.4%)
Sep 2020
-
$3.63B(+52.0%)
Jun 2020
-
$2.39B(+34.3%)
Mar 2020
-
$1.78B(-27.1%)
Dec 2019
$2.44B(-67.1%)
$2.44B(+47.5%)
Sep 2019
-
$1.65B(-30.2%)
Jun 2019
-
$2.37B(+10.8%)
Mar 2019
-
$2.14B(-71.2%)
Dec 2018
$7.41B(-7.8%)
$7.41B(-18.0%)
Sep 2018
-
$9.04B(+30.8%)
Jun 2018
-
$6.91B(+44.3%)
Mar 2018
-
$4.79B(-40.4%)
Dec 2017
$8.03B(+33.0%)
$8.03B(+15.7%)
Sep 2017
-
$6.94B(+27.8%)
Jun 2017
-
$5.43B(+55.0%)
Mar 2017
-
$3.51B(-41.9%)
Dec 2016
$6.04B(+35.6%)
$6.04B(+42.9%)
Sep 2016
-
$4.23B(+7.4%)
Jun 2016
-
$3.93B(+31.4%)
Mar 2016
-
$3.00B(-32.7%)
Dec 2015
$4.45B(-7.8%)
$4.45B(+3.1%)
Sep 2015
-
$4.32B(+2.1%)
Jun 2015
-
$4.23B(+2.2%)
Mar 2015
-
$4.14B(-14.2%)
Dec 2014
$4.83B(-10.6%)
$4.83B(+0.4%)
Sep 2014
-
$4.81B(-6.2%)
Jun 2014
-
$5.13B(-1.6%)
Mar 2014
-
$5.21B(-3.4%)
Dec 2013
$5.40B(-5.0%)
$5.40B(+0.3%)
Sep 2013
-
$5.38B(+14.2%)
Jun 2013
-
$4.71B(-0.5%)
Mar 2013
-
$4.73B(-16.7%)
Dec 2012
$5.68B(-17.6%)
$5.68B(-17.6%)
Sep 2012
-
$6.90B(+31.1%)
Jun 2012
-
$5.26B(+6.8%)
Mar 2012
-
$4.92B(-28.6%)
Dec 2011
$6.90B(+2.5%)
$6.90B(+1.7%)
Sep 2011
-
$6.78B(+7.2%)
Jun 2011
-
$6.33B(-5.7%)
Mar 2011
-
$6.71B(-0.2%)
Dec 2010
$6.73B(+49.6%)
$6.73B(+9.6%)
Sep 2010
-
$6.14B(+18.2%)
Jun 2010
-
$5.20B(+9.2%)
Mar 2010
-
$4.76B(+5.8%)
Dec 2009
$4.50B
$4.50B(+14.5%)
Sep 2009
-
$3.93B(+12.6%)
Jun 2009
-
$3.49B(-0.5%)
DateAnnualQuarterly
Mar 2009
-
$3.51B(-40.8%)
Dec 2008
$5.93B(+22.7%)
$5.93B(-3.1%)
Sep 2008
-
$6.12B(+18.4%)
Jun 2008
-
$5.17B(-4.9%)
Mar 2008
-
$5.43B(+12.5%)
Dec 2007
$4.83B(+24.2%)
$4.83B(+35.5%)
Sep 2007
-
$3.57B(+18.7%)
Jun 2007
-
$3.00B(-10.7%)
Mar 2007
-
$3.36B(-13.5%)
Dec 2006
$3.89B(-22.8%)
$3.89B(+7.5%)
Sep 2006
-
$3.62B(-21.2%)
Jun 2006
-
$4.59B(+1.9%)
Mar 2006
-
$4.50B(-10.6%)
Dec 2005
$5.04B(-32.5%)
$5.04B(-19.2%)
Sep 2005
-
$6.23B(+15.4%)
Jun 2005
-
$5.40B(-3.9%)
Mar 2005
-
$5.62B(+67.4%)
Dec 2004
$7.46B(+101.0%)
-
Dec 2003
$3.71B(+1.6%)
-
Dec 2002
$3.65B(+80.5%)
-
Sep 1999
-
$3.36B(+60.2%)
Jun 1999
-
$2.10B(-14.4%)
Mar 1999
-
$2.45B(+51.6%)
Sep 1998
-
$1.62B(+16.9%)
Jun 1998
-
$1.38B(+4.1%)
Mar 1998
-
$1.33B(-31.8%)
Dec 1997
$2.02B(+210.5%)
$1.95B(+29.5%)
Sep 1997
-
$1.50B(-18.8%)
Jun 1997
-
$1.85B(+77.8%)
Mar 1997
-
$1.04B(+28.1%)
Dec 1996
-
$813.70M(+10.2%)
Sep 1996
-
$738.10M(-34.4%)
Jun 1996
-
$1.13B(+25.2%)
Mar 1996
-
$898.40M(-10.1%)
Dec 1995
-
$999.50M(+2.4%)
Sep 1995
-
$976.20M(-1.4%)
Jun 1995
-
$989.70M(+1.1%)
Mar 1995
-
$978.80M(+82.3%)
Dec 1994
-
$536.90M(-46.3%)
Sep 1994
-
$999.60M(+41.4%)
Jun 1994
-
$706.80M(+16.8%)
Mar 1994
-
$604.90M(+12.1%)
Dec 1993
-
$539.60M(-15.2%)
Sep 1993
-
$636.10M(+42.1%)
Jun 1993
-
$447.70M(-24.7%)
Mar 1993
-
$594.60M(+37.5%)
Dec 1992
-
$432.40M(+21.7%)
Sep 1992
-
$355.20M(-16.5%)
Jun 1992
-
$425.40M(+21.1%)
Mar 1992
-
$351.30M(-26.7%)
Dec 1991
-
$479.20M(+63.3%)
Sep 1991
-
$293.50M(+27.4%)
Jun 1991
-
$230.40M(-23.9%)
Mar 1991
-
$302.80M(-13.5%)
Dec 1990
-
$350.20M(-29.1%)
Sep 1990
-
$494.00M(+7.6%)
Jun 1990
-
$459.10M(+9.5%)
Mar 1990
-
$419.30M(+29.8%)
Dec 1989
$652.00M(-14.4%)
$323.00M(-45.0%)
Sep 1989
-
$587.40M(+2.6%)
Jun 1989
-
$572.40M(-24.8%)
Dec 1988
$761.50M(-26.1%)
$761.50M(-26.1%)
Dec 1987
$1.03B(+112.1%)
$1.03B(+112.1%)
Dec 1986
$486.00M(+19.7%)
$486.00M(+19.7%)
Dec 1985
$406.10M(-8.8%)
$406.10M(-8.8%)
Dec 1984
$445.30M
$445.30M

FAQ

  • What is Eli Lilly and Company annual cash & cash equivalents?
  • What is the all time high annual cash & cash equivalents for Eli Lilly and Company?
  • What is Eli Lilly and Company annual cash & cash equivalents year-on-year change?
  • What is Eli Lilly and Company quarterly cash & cash equivalents?
  • What is the all time high quarterly cash & cash equivalents for Eli Lilly and Company?
  • What is Eli Lilly and Company quarterly cash & cash equivalents year-on-year change?

What is Eli Lilly and Company annual cash & cash equivalents?

The current annual cash & cash equivalents of LLY is $3.42B

What is the all time high annual cash & cash equivalents for Eli Lilly and Company?

Eli Lilly and Company all-time high annual cash & cash equivalents is $8.03B

What is Eli Lilly and Company annual cash & cash equivalents year-on-year change?

Over the past year, LLY annual cash & cash equivalents has changed by +$495.50M (+16.92%)

What is Eli Lilly and Company quarterly cash & cash equivalents?

The current quarterly cash & cash equivalents of LLY is $3.55B

What is the all time high quarterly cash & cash equivalents for Eli Lilly and Company?

Eli Lilly and Company all-time high quarterly cash & cash equivalents is $9.04B

What is Eli Lilly and Company quarterly cash & cash equivalents year-on-year change?

Over the past year, LLY quarterly cash & cash equivalents has changed by +$182.00M (+5.41%)
On this page